US biosimilar activity rises, but is the first filing imminent?
This article was originally published in SRA
Executive Summary
With the launch of biosimilar Remicade in February marking another reference point in Europe's expanding biosimilars landscape1, the question arises: When can we expect the first biosimilar filing in the US? No one's saying, but the steady rise in sponsor-Food and Drug Administration activity over the past few years suggests it may not be long now.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.